Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Weighted Average) (2016 - 2025)

Mimedx's Shares Outstanding (Weighted Average) history spans 15 years, with the latest figure at $147.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 0.55% year-over-year to $147.8 million; the TTM value through Dec 2025 reached $147.8 million, up 0.55%, while the annual FY2025 figure was $147.8 million, 0.55% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $147.8 million at Mimedx, roughly flat from $147.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $147.8 million in Q4 2025 and bottomed at $109.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $115.7 million (2023), against an average of $126.5 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 27.98% in 2024 before it grew 0.49% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $110.4 million in 2021, then increased by 2.32% to $112.9 million in 2022, then grew by 3.18% to $116.5 million in 2023, then increased by 26.17% to $147.0 million in 2024, then increased by 0.55% to $147.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Shares Outstanding (Weighted Average) are $147.8 million (Q4 2025), $147.7 million (Q3 2025), and $147.8 million (Q2 2025).